IRAV (FLJ11286), an interferon-stimulated gene with antiviral activity against dengue virus, interacts with MOV10

Journal of Virology

Volumn 91, Issue 5, 2017, Pages

  Balinsky, Corey A ^a   Schmeisser, Hana ^a   Wells, Alexandra I ^a   Ganesan, Sundar ^a   Jin, Tengchuan ^a   Singh, Kavita ^a   Zoon, Kathryn C ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

C19orf66; Dengue; Flavivirus; FLJ11286; Interferon; IRAV; MOV10; P body; UPF0515

Indexed keywords

DCP1A PROTEIN; DDX6 PROTEIN; ELAV LIKE PROTEIN 1; G3BP1 PROTEIN; IRAV PROTEIN; MOV10 PROTEIN; RCK PROTEIN; RIBONUCLEOPROTEIN; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; UPF1 PROTEIN; VIRUS RNA; XRN1 PROTEIN; IRAV PROTEIN, HUMAN; MOV10 PROTEIN, HUMAN; RNA HELICASE;

ANTIVIRAL ACTIVITY; ARTICLE; COIMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IRAV GENE; PROTEIN DEPLETION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; UPREGULATION; VIRUS GENE; VIRUS REPLICATION; WESTERN BLOTTING; A-549 CELL LINE; AEDES; ANIMAL; CHLOROCEBUS AETHIOPS; GENE EXPRESSION; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PHYSIOLOGY; PROTEIN TRANSPORT; TRANSCRIPTION INITIATION; VERO CELL LINE;

A549 CELLS; AEDES; ANIMALS; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; GENE EXPRESSION; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; PROTEIN TRANSPORT; RNA HELICASES; RNA-BINDING PROTEINS; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION; VERO CELLS; VIRUS REPLICATION;

EID: 85013946224     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01606-16     Document Type: Article

References (73)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GRW, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. https://doi.org/10.1038/nature12060.
2. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martínez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW. 2010. Dengue: a continuing global threat. Nat Rev Microbiol 8:S7-S16. https://doi.org/10.1038/nrmicro2460.
3. Kyle JL, Harris E. 2008. Global spread and persistence of dengue. Annu Rev Microbiol 62:71-92. https://doi.org/10.1146/annurev.micro.62.081307.163005.
4. WHO. 2006. WHO scientific working group report on dengue; reference number TDR/SWG/08. WHO, Geneva, Switzerland.
5. Schneider WM, Chevillotte MD, Rice CM. 2014. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32:513-545. https://doi.org/10.1146/annurev-immunol-032713-120231.
6. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485. https://doi.org/10.1038/nature09907.
7. Schoggins JW. 2014. Interferon-stimulated genes: roles in viral pathogenesis. Curr Opin Virol 6:40-46. https://doi.org/10.1016/j.coviro.2014.03.006.
8. Warke RV, Martin KJ, Giaya K, Shaw SK, Rothman AL, Bosch I. 2008. TRAIL is a novel antiviral protein against dengue virus. J Virol 82:555-564. https://doi.org/10.1128/JVI.01694-06.
9. Brass AL, Huang I-C, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, Adams DJ, Xavier RJ, Farzan M, Elledge SJ. 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139: 1243-1254. https://doi.org/10.1016/j.cell.2009.12.017.
10. Helbig KJ, Carr JM, Calvert JK, Wati S, Clarke JN, Eyre NS, Narayana SK, Fiches GN, McCartney EM, Beard MR. 2013. Viperin is induced following dengue virus type-2 (DENV-2) infection and has anti-viral actions requiring the C-terminal end of viperin. PLoS Negl Trop Dis 7:e2178. https://doi.org/10.1371/journal.pntd.0002178.
11. Jiang D, Weidner JM, Qing M, Pan X-B, Guo H, Xu C, Zhang X, Birk A, Chang J, Shi P-Y, Block TM, Guo J-T. 2010. Identification of five interferon-induced cellular proteins that inhibit West Nile virus and dengue virus infections. J Virol 84:8332-8341. https://doi.org/10.1128/JVI.02199-09.
12. Liu B, Li NL, Wang J, Shi P-Y, Wang T, Miller MA, Li K. 2014. Overlapping and distinct molecular determinants dictating the antiviral activities of TRIM56 against flaviviruses and coronavirus. J Virol 88:13821-13835. https://doi.org/10.1128/JVI.02505-14.
13. Cho H, Shrestha B, Sen GC, Diamond MS. 2013. A role for Ifit2 in restricting West Nile virus infection in the brain. J Virol 87:8363-8371. https://doi.org/10.1128/JVI.01097-13.
14. Raychoudhuri A, Shrivastava S, Steele R, Kim H, Ray R, Ray RB. 2011. ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol 85:12881-12889. https://doi.org/10.1128/JVI.05633-11.
15. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. 2010. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J Gen Virol 91:382-388. https://doi.org/10.1099/vir.0.015388-0.
16. Sadeghi F, Bokharaei-Salim F, Salehi-Vaziri M, Monavari SH, Alavian SM, Salimi S, Vahabpour R, Keyvani H. 2014. Associations between human TRIM22 gene expression and the response to combination therapy with Peg-IFNγ-2a and ribavirin in Iranian patients with chronic hepatitis C. J Med Virol 86:1499-1506. https://doi.org/10.1002/jmv.23985.
17. Taylor RT, Lubick KJ, Robertson SJ, Broughton JP, Bloom ME, Bresnahan WA, Best SM. 2011. TRIM79α, an interferon-stimulated gene product, restricts tick-borne encephalitis virus replication by degrading the viral RNA polymerase. Cell Host Microbe 10:185-196. https://doi.org/10.1016/j.chom.2011.08.004.
18. Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, Errett J, Lin T-Y, Schneller S, Zust R, Dong H, Thiel V, Sen GC, Fensterl V, Klimstra WB, Pierson TC, Buller RM, Gale M, Shi P-Y, Diamond MS. 2010. 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468:452-456. https://doi.org/10.1038/nature09489.
19. Li J, Ding SC, Cho H, Chung BC, Gale M, Chanda SK, Diamond MS. 2013. A short hairpin RNA screen of interferon-stimulated genes identifies a novel negative regulator of the cellular antiviral response. mBio 4:e00385-00313. https://doi.org/10.1128/mBio.00385-13.
20. Schmeisser H, Mejido J, Balinsky CA, Morrow AN, Clark CR, Zhao T, Zoon KC. 2010. Identification of alpha interferon-induced genes associated with antiviral activity in Daudi cells and characterization of IFIT3 as a novel antiviral gene. J Virol 84:10671-10680. https://doi.org/10.1128/JVI.00818-10.
21. Balinsky CA, Schmeisser H, Zoon KC. 2014. Characterization of a novel interferon stimulated gene with antiviral activity. Cytokine 70:28-29.
22. Balinsky CA, Schmeisser H, Ganesan S, Jin T, Singh K, Zoon KC. 2015. Characterization of a novel interferon stimulated gene with antiviral activity against dengue virus. Cytokine 76:86.
23. Suzuki Y, Chin W-X, Han Q, Ichiyama K, Lee CH, Eyo ZW, Ebina H, Takahashi H, Takahashi C, Tan BH, Hishiki T, Ohba K, Matsuyama T, Koyanagi Y, Tan Y-J, Sawasaki T, Chu JJH, Vasudevan SG, Sano K, Yamamoto N. 2016. Characterization of RyDEN (C19orf66) as an interferon-stimulated cellular inhibitor against dengue virus replication. PLoS Pathog 12:e1005357. https://doi.org/10.1371/journal.ppat.1005357.
24. Singh MK, Scott TF, LaFramboise WA, Hu FZ, Post JC, Ehrlich GD. 2007. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci 258:52-59. https://doi.org/10.1016/j.jns.2007.02.034.
25. Taylor MW, Tsukahara T, McClintick JN, Edenberg HJ, Kwo P. 2008. Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med 6:66. https://doi.org/10.1186/1479-5876-6-66.
26. Zimmerer JM, Lesinski GB, Ruppert AS, Radmacher MD, Noble C, Kendra K, Walker MJ, Carson WE. 2008. Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to interferon-alpha. Clin Cancer Res 14:5900-5906. https://doi.org/10.1158/1078-0432.CCR-08-0846.
27. Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR, Castro E, Akondy R, Rinfret A, Yassine-Diab B, Said EA, Chouikh Y, Cameron MJ, Clum R, Kelvin D, Somogyi R, Greller LD, Balderas RS, Wilkinson P, Pantaleo G, Tartaglia J, Haddad EK, Sékaly R-P. 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 205: 3119-3131. https://doi.org/10.1084/jem.20082292.
28. Harvey SAK, Romanowski EG, Yates KA, Gordon YJ. 2005. Adenovirusdirected ocular innate immunity: the role of conjunctival defensin-like chemokines (IP-10, I-TAC) and phagocytic human defensin-alpha. Invest Ophthalmol Vis Sci 46:3657-3665. https://doi.org/10.1167/iovs.05-0438.
29. Wang J, Nikrad MP, Phang T, Gao B, Alford T, Ito Y, Edeen K, Travanty EA, Kosmider B, Hartshorn K, Mason RJ. 2011. Innate immune response to influenza A virus in differentiated human alveolar type II cells. Am J Respir Cell Mol Biol 45:582-591. https://doi.org/10.1165/rcmb.2010-0108OC.
30. Zapata JC, Carrion R, Patterson JL, Crasta O, Zhang Y, Mani S, Jett M, Poonia B, Djavani M, White DM, Lukashevich IS, Salvato MS. 2013. Transcriptome analysis of human peripheral blood mononuclear cells exposed to Lassa virus and to the attenuated Mopeia/Lassa reassortant 29 (ML29), a vaccine candidate. PLoS Negl Trop Dis 7:e2406. https://doi.org/10.1371/journal.pntd.0002406.
31. Kash JC, Mühlberger E, Carter V, Grosch M, Perwitasari O, Proll SC, Thomas MJ, Weber F, Klenk H-D, Katze MG. 2006. Global suppression of the host antiviral response by Ebola-and Marburg viruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol 80:3009-3020. https://doi.org/10.1128/JVI.80.6.3009-3020.2006.
32. Bull TM, Meadows CA, Coldren CD, Moore M, Sotto-Santiago SM, Nana-Sinkam SP, Campbell TB, Geraci MW. 2008. Human herpesvirus-8 infection of primary pulmonary microvascular endothelial cells. Am J Respir Cell Mol Biol 39:706-716. https://doi.org/10.1165/rcmb.2007-0368OC.
33. Miyazaki D, Haruki T, Takeda S, Sasaki S-I, Yakura K, Terasaka Y, Komatsu N, Yamagami S, Touge H, Touge C, Inoue Y. 2011. Herpes simplex virus type 1-induced transcriptional networks of corneal endothelial cells indicate antigen presentation function. Invest Ophthalmol Vis Sci 52: 4282-4293. https://doi.org/10.1167/iovs.10-6911.
34. de Chassey B, Navratil V, Tafforeau L, Hiet MS, Aublin-Gex A, Agaugué S, Meiffren G, Pradezynski F, Faria BF, Chantier T, Le Breton M, Pellet J, Davoust N, Mangeot PE, Chaboud A, Penin F, Jacob Y, Vidalain PO, Vidal M, André P, Rabourdin-Combe C, Lotteau V. 2008. Hepatitis C virus infection protein network. Mol Syst Biol 4:230.
35. Mi H, Muruganujan A, Thomas PD. 2013. PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees. Nucleic Acids Res 41:D377-D386. https://doi.org/10.1093/nar/gks1118.
36. Gregersen LH, Schueler M, Munschauer M, Mastrobuoni G, Chen W, Kempa S, Dieterich C, Landthaler M. 2014. MOV10 is a 5' to 3' RNA helicase contributing to UPF1 mRNA target degradation by translocation along 3' UTRs. Mol Cell 54:573-585. https://doi.org/10.1016/j.molcel.2014.03.017.
37. Chahar HS, Chen S, Manjunath N. 2013. P-body components LSM1, GW182, DDX3, DDX6 and XRN1 are recruited to WNV replication sites and positively regulate viral replication. Virology 436:1-7. https://doi.org/10.1016/j.virol.2012.09.041.
38. Burdick R, Smith JL, Chaipan C, Friew Y, Chen J, Venkatachari NJ, Delviks-Frankenberry KA, Hu W-S, Pathak VK. 2010. P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages. J Virol 84:10241-10253. https://doi.org/10.1128/JVI.00585-10.
39. Furtak V, Mulky A, Rawlings SA, Kozhaya L, Lee K, Kewalramani VN, Unutmaz D. 2010. Perturbation of the P-body component Mov10 inhibits HIV-1 infectivity. PLoS One 5:e9081. https://doi.org/10.1371/journal.pone.0009081.
40. Izumi T, Burdick R, Shigemi M, Plisov S, Hu W-S, Pathak VK. 2013. Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity. J Virol 87:11047-11062. https://doi.org/10.1128/JVI.02070-13.
41. Wang X, Han Y, Dang Y, Fu W, Zhou T, Ptak RG, Zheng Y-H. 2010. Moloney leukemia virus 10 (MOV10) protein inhibits retrovirus replication. J Biol Chem 285:14346-14355. https://doi.org/10.1074/jbc. M110.109314.
42. Ma Y-X, Li D, Fu L-J, Fu B-Q, Chen S-J, Xu W-Z, Teng X, Song Z-W, Gu H-X. 2015. The role of Moloney leukemia virus 10 in hepatitis B virus expression in hepatoma cells. Virus Res 197:85-91. https://doi.org/10.1016/j.virusres.2014.12.011.
43. Decker CJ, Parker R. 2012. P-bodies and stress granules: possible roles in the control of translation and mRNA degradation. Cold Spring Harb Perspect Biol 4:a012286. https://doi.org/10.1101/cshperspect.a012286.
44. Chapman EG, Moon SL, Wilusz J, Kieft JS. 2014. RNA structures that resist degradation by Xrn1 produce a pathogenic Dengue virus RNA. eLife 3:e01892. https://doi.org/10.7554/eLife.01892.
45. Manokaran G, Finol E, Wang C, Gunaratne J, Bahl J, Ong EZ, Tan HC, Sessions OM, Ward AM, Gubler DJ, Harris E, Garcia-Blanco MA, Ooi EE. 2015. Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science 350:217-221. https://doi.org/10.1126/science.aab3369.
46. Moon SL, Anderson JR, Kumagai Y, Wilusz CJ, Akira S, Khromykh AA, Wilusz J. 2012. A noncoding RNA produced by arthropod-borne flaviviruses inhibits the cellular exoribonuclease XRN1 and alters host mRNA stability. RNA 18:2029-2040. https://doi.org/10.1261/rna.034330.112.
47. Ward AM, Bidet K, Yinglin A, Ler SG, Hogue K, Blackstock W, Gunaratne J, Garcia-Blanco MA. 2011. Quantitative mass spectrometry of DENV-2 RNA-interacting proteins reveals that the DEAD-box RNA helicase DDX6 binds the DB1 and DB2 3' UTR structures. RNA Biol 8:1173-1186. https://doi.org/10.4161/rna.8.6.17836.
48. Pérez-Vilaró G, Fernández-Carrillo C, Mensa L, Miquel R, Sanjuan X, Forns X, Pérez-Del-Pulgar S, Díez J. 2015. Hepatitis C virus infection inhibits P-body granule formation in human livers. J Hepatol 62:785-790. https://doi.org/10.1016/j.jhep.2014.11.018.
49. Dougherty JD, White JP, Lloyd RE. 2011. Poliovirus-mediated disruption of cytoplasmic processing bodies. J Virol 85:64-75. https://doi.org/10.1128/JVI.01657-10.
50. Mok BW-Y, Song W, Wang P, Tai H, Chen Y, Zheng M, Wen X, Lau S-Y, Wu WL, Matsumoto K, Yuen K-Y, Chen H. 2012. The NS1 protein of influenza A virus interacts with cellular processing bodies and stress granules through RNA-associated protein 55 (RAP55) during virus infection. J Virol 86:12695-12707. https://doi.org/10.1128/JVI.00647-12.
51. Cheng E, Mir MA. 2012. Signatures of host mRNA 5' terminus for efficient hantavirus cap snatching. J Virol 86:10173-10185. https://doi.org/10.1128/JVI.05560-11.
52. Hopkins K, Cherry S. 2013. Bunyaviral cap-snatching vs. decapping: recycling cell cycle mRNAs. Cell Cycle 12:3711-3712. https://doi.org/10.4161/cc.26878.
53. Lloyd RE. 2013. Regulation of stress granules and P-bodies during RNA virus infection. Wiley Interdiscip Rev RNA 4:317-331. https://doi.org/10.1002/wrna.1162.
54. Liu C, Zhang X, Huang F, Yang B, Li J, Liu B, Luo H, Zhang P, Zhang H. 2012. APOBEC3G inhibits microRNA-mediated repression of translation by interfering with the interaction between Argonaute-2 and MOV10. J Biol Chem 287:29373-29383. https://doi.org/10.1074/jbc. M112.354001.
55. Goodier JL, Pereira GC, Cheung LE, Rose RJ, Kazazian HH. 2015. The broad-spectrum antiviral protein ZAP restricts human retrotransposition. PLoS Genet 11:e1005252. https://doi.org/10.1371/journal.pgen.1005252.
56. Goodier JL, Cheung LE, Kazazian HH. 2012. MOV10 RNA helicase is a potent inhibitor of retrotransposition in cells. PLoS Genet 8:e1002941. https://doi.org/10.1371/journal.pgen.1002941.
57. Li X, Zhang J, Jia R, Cheng V, Xu X, Qiao W, Guo F, Liang C, Cen S. 2013. The MOV10 helicase inhibits LINE-1 mobility. J Biol Chem 288: 21148-21160. https://doi.org/10.1074/jbc. M113.465856.
58. Taylor MS, Lacava J, Mita P, Molloy KR, Huang CRL, Li D, Adney EM, Jiang H, Burns KH, Chait BT, Rout MP, Boeke JD, Dai L. 2013. Affinity proteomics reveals human host factors implicated in discrete stages of LINE-1 retrotransposition. Cell 155:1034-1048. https://doi.org/10.1016/j.cell.2013.10.021.
59. Kenny PJ, Zhou H, Kim M, Skariah G, Khetani RS, Drnevich J, Arcila ML, Kosik KS, Ceman S. 2014. MOV10 and FMRP regulate AGO2 association with microRNA recognition elements. Cell Rep 9:1729-1741. https://doi.org/10.1016/j.celrep.2014.10.054.
60. Cuevas RA, Ghosh A, Wallerath C, Hornung V, Coyne CB, Sarkar SN. 2016. MOV10 provides antiviral activity against RNA viruses by enhancing RIG-I-MAVS-independent IFN induction. J Immunol 196:3877-3886. https://doi.org/10.4049/jimmunol.1501359.
61. Zhang J, Huang F, Tan L, Bai C, Chen B, Liu J, Liang J, Liu C, Zhang S, Lu G, Chen Y, Zhang H. 2016. Host protein Moloney leukemia virus 10 (MOV10) acts as a restriction factor of influenza A virus by inhibiting the nuclear import of the viral nucleoprotein. J Virol 90:3966-3980. https://doi.org/10.1128/JVI.03137-15.
62. Imamachi N, Tani H, Akimitsu N. 2012. Up-frameshift protein 1 (UPF1): multitalented entertainer in RNA decay. Drug Discov Ther 6:55-61.
63. Balistreri G, Horvath P, Schweingruber C, Zünd D, McInerney G, Merits A, Mühlemann O, Azzalin C, Helenius A. 2014. The host nonsense-mediated mRNA decay pathway restricts mammalian RNA virus replication. Cell Host Microbe 16:403-411. https://doi.org/10.1016/j.chom.2014.08.007.
64. Serquiña AKP, Das SR, Popova E, Ojelabi OA, Roy CK, Göttlinger HG. 2013. UPF1 is crucial for the infectivity of human immunodeficiency virus type 1 progeny virions. J Virol 87:8853-8861. https://doi.org/10.1128/JVI.00925-13.
65. Wang H, Ding N, Guo J, Xia J, Ruan Y. 2016. Dysregulation of TTP and HuR plays an important role in cancers. Tumour Biol 37:14451-14461. https://doi.org/10.1007/s13277-016-5397-z.
66. Barnhart MD, Moon SL, Emch AW, Wilusz CJ, Wilusz J. 2013. Changes in cellular mRNA stability, splicing, and polyadenylation through HuR protein sequestration by a cytoplasmic RNA virus. Cell Rep 5:909-917. https://doi.org/10.1016/j.celrep.2013.10.012.
67. Shwetha S, Kumar A, Mullick R, Vasudevan D, Mukherjee N, Das S. 2015. HuR displaces polypyrimidine tract binding protein to facilitate La binding to the 3' untranslated region and enhances hepatitis C virus replication. J Virol 89:11356-11371. https://doi.org/10.1128/JVI.01714-15.
68. Hung C-M, Huang W-C, Pan H-L, Chien P-H, Lin C-W, Chen L-C, Chien Y-F, Lin C-C, Leow K-H, Chen W-S, Chen J-Y, Ho C-Y, Hou P-S, Chen Y-J. 2014. Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells. Biomed Res Int 2014: 827415 https://doi.org/10.1155/2014/827415.
69. Lin J-Y, Brewer G, Li M-L. 2015. HuR and Ago2 bind the internal ribosome entry site of enterovirus 71 and promote virus translation and replication. PLoS One 10:e0140291. https://doi.org/10.1371/journal.pone.0140291.
70. Blaney JE, Hanson CT, Hanley KA, Murphy BR, Whitehead SS. 2004. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect Dis 4:39. https://doi.org/10.1186/1471-2334-4-39.
71. Gubler DJ, Reed D, Rosen L, Hitchcock JR. 1978. Epidemiologic, clinical, and virologic observations on dengue in the Kingdom of Tonga. Am J Trop Med Hyg 27:581-589.
72. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E. 2000. Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 74:4957-4966. https://doi.org/10.1128/JVI.74.11.4957-4966.2000.
73. Balinsky CA, Schmeisser H, Ganesan S, Singh K, Pierson TC, Zoon KC. 2013. Nucleolin interacts with the dengue virus capsid protein and plays a role in formation of infectious virus particles. J Virol 87:13094-13106. https://doi.org/10.1128/JVI.00704-13.